Novartis’s Sandoz Boosts Biosimilar Power with $350 M Just‑Evotec Buy
Read how Sandoz’s $350 M acquisition of Just‑Evotec Biologics boosts its continuous‑manufacturing biosimilar capacity, cutting costs and speeding market launch for affordable biologics.
3 minutes to read








